Telix Pharmaceuticals Advances Radiopharma Platform with Key Trials and US Manufacturing Shift

Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer. The company also reported positive results from Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in prostate cancer. Additionally, Telix expanded its U.S. manufacturing footprint with new cyclotron installations to support in-house radioisotope production and supply resilience. These developments highlight the company's progress in diagnostics, therapeutics, and infrastructure, with a focus on neuro-oncology and prostate cancer.